For each citation that was shared on social media (LinkedIn, Facebook, or Twitter) with the “@GenScript” tag, the author will be rewarded with a $10 Amazon gift card or 2,000 GS points.

Immunity-and-Matrix-Regulatory Cells Derived from Human Embryonic Stem Cells Safely and Effectively Treat Mouse Lung Injury and Fibrosis

biorxiv. 2020-04; 
Jun Wu, Dingyun Song, Zhongwen Li, Baojie Guo, Yani Xiao, Wenjing Liu, Lingmin Liang, Chunjing Feng, Tingting Gao, Zai Wang, Jianyan Wen, Shengnan Yang, Peipei Liu, Lei Wang, Yukai Wang, Liang Peng, Guihai Feng, Shiqiang Huang, Glyn Nigel Stacey, Wei Li, Yan Huo, Ronghua Jin, Qi Zhou, Liu Wang, Baoyang Hu, Huaping Dai, Jie Hao
Products/Services Used Details Operation
Cellular Analysis Clinical hESCs were tested weekly for mycoplasma contamination using a Myco-detection Kit (InvivoGen, San Diego, CA, USA; rep-pt1) and endotoxin contamination was tested using a ToxinSensorTM 125 Chromogenic LAL Endotoxin Assay Kit (GenScript, Piscataway, NJ, USA; L00350). Get A Quote

Abstract

Lung injury and fibrosis represent the most significant outcomes of severe and acute lung disorders, including COVID-19. However, there are still no effective drugs to treat lung injury and fibrosis. In this study, we report the generation of clinical-grade human embryonic stem cells (hESCs)-derived immunity- and matrix-regulatory cells (IMRCs) manufactured under good manufacturing practice (GMP) requirements, that can treat lung injury and fibrosis in vivo. We generate IMRCs through sequentially differentiating hESCs with xeno-free reagents. IMRCs possess a unique gene expression profile distinct from umbilical cord mesenchymal stem cells (UCMSCs), such as higher levels of proliferative, immunomodulatory and a... More

Keywords